Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183949 · ClinicalTrials.gov registry record · Phase 1
Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT01183949: Completed Phase 1 study of Multiple Myeloma, sponsored by Astex Pharmaceuticals.
NCT01183949 is a Phase 1 study of Multiple Myeloma that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 18 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01183949, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
Primary Outcome
Efficacy will be assessed using the International Multiple Myeloma Working Group (IMWG) Response Criteria
Conditions Studied
Interventions
- DRUG Bortezomib
- DRUG AT7519M
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
- Dana Faber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Centre - New York
Wisconsin
- MCW and Froedtert Clinical Cancer Center, Division of Neoplastic Diseases & Related Disorders - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
What the finished NCT01183949 record still lists
NCT01183949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Bortezomib is the first listed.
NCT01183949 lists 5 locations in 3 states (Massachusetts, New York, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT01183949 about?
NCT01183949 is a clinical study titled "Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma". The purpose of this study is to determine whether AT7519M alone or AT7519M plus bortezomib are effective treatments in patients with previously treated multiple myeloma.
What is the current status of trial NCT01183949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-11. Estimated completion is 2015-03.
What conditions does trial NCT01183949 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT01183949?
The interventions under investigation include: Bortezomib (DRUG), AT7519M (DRUG).
Who is sponsoring clinical trial NCT01183949?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01183949 being conducted?
This trial has 5 study locations across Massachusetts, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01183949's enrollment target sits among peer trials
18 394th of 438 higher than 41 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia